Top

Published in:

Open Access 01-07-2007 | ORIGINAL COMMUNICATION

Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy

Authors: E. L. van der Kooi, MD, J. S. Kalkman, MSc, E. Lindeman, MD, PhD, J. C. M. Hendriks, PhD, B. G. M. van Engelen, MD, PhD, G. Bleijenberg, PhD, G. W. Padberg, MD, PhD

Published in: Journal of Neurology | Issue 7/2007

Abstract

Background

We recently reported a randomised controlled trial on the efficacy of strength training and the β 2-adrenergic agonist albuterol in patients with facioscapulohumeral muscular dystrophy (FSHD). Strength training and albuterol appeared safe interventions with limited positive effect on muscle strength and volume. We concurrently explored the prevalence and the characteristics of pain and fatigue in the participating FSHD patients, because these are probably underreported but clinically relevant symptoms in this disorder. Next, we studied the effects of albuterol and strength training on pain, experienced fatigue, healthrelated functional status and psychological distress.

Methods

Sixty-five patients were randomised to strength training of elbow flexors and ankle dorsiflexors or nontraining. After 26 weeks, albuterol (sustained-release, 8 mg bid) was added in a randomised, doubleblind, placebo-controlled design. Outcomes comprised self-reported pain, experienced fatigue, functional status and psychological distress obtained with validated questionnaires at 52 weeks.

Results

Eighty percent of patients reported chronic persistent or periodic, multifocal pains. Thirtyfour percent of the participants were severely fatigued. Strength training and albuterol failed to have a significant effect on all outcomes.

Conclusions

Pain and fatigue are important features in FSHD. Strength training and albuterol do not have a positive or negative effect on pain, experienced fatigue, functional status and psychological distress.

Aitkens SG, McCrory MA, Kilmer DD, Bernauer EM (1993) Moderate resistance exercise program: its effect in slowly progressive neuromuscular disease. Arch Phys Med Rehabil 74:711–715CrossRefPubMed

American College of Sports Medicine Position Stand (1998) The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc 30:975–991

American College of Sports Medicine Position Stand (2002) Progression models in resistance training for healthy adults. Med Sci Sports Exerc 34:364–380CrossRef

Arahata K, Ishihara T, Fukunaga H, et al. (1995) Inflammatory response in facioscapulohumeral dystrophy (FSHD): immunocytochemical and genetic analysis. Muscle Nerve 2:S56–S66CrossRefPubMed

Arindell WA, Ettema JHM (1986) SCL- 90, handleiding bij multidimensionele psychopathologie-indicator. Swets & Zeitlinger BV, Amsterdam

Association Française contre les Myopathies (AFM) (1998) La monographie Myoline ’dystrophie musculaire facio-scapulo-humérale’. Evry Cedex

Beck AT, Guth D, Steer RA, Ball R (1997) Screening for major depression disorders in medical inpatients with the Beck Depression Inventory for Primary Care. Behav Res Ther 35:785–791CrossRefPubMed

Bergner M, Bobbit RA, Carter WB, Gilson BS (1981) The Sickness Impact Scale: development and final revision of a health status measure. Med Care 19:787–705CrossRefPubMed

Brouwer OF, Padberg GW, van der Ploeg RJ, Ruys CJ, Brand R (1992) The influence of handedness on the distribution of muscular weakness of the arm in facioscapulohumeral muscular dystrophy. Brain 115:1587–1598CrossRefPubMed

10.

Bushby KMD, Pollitt C, Johnson MA, Rogers MT, Chinnery PF (1998) Muscle pain as a prominent feature of facioscapulohumeral muscular dystrophy (FSHD): four illustrative case reports. Neuromuscul Disord 8:574–579CrossRefPubMed

11.

Caruso JF, Signorile JF, Perry AC, et al. (1995) The effects of albuterol and isokinetic exercise on the quadriceps muscle group. Med Sci Sports Exerc 27:1471–1476PubMed

12.

Chaudhuri A, Behan PO (2004) Fatigue in neurological disorders Lancet 363:978–988CrossRefPubMed

13.

Dittner AJ, Wessely SC, Brown RG (2004) The assessment of fatigue, a practical guide for clinicians and researchers. J Psychosom Res 56:157–1170CrossRefPubMed

14.

Dupont-Versteegden EE (1996) Exercise and clenbuterol as strategies to decrease the progression of muscular dystrophy in mdx mice. J Appl Physiol 80:734–741CrossRefPubMed

15.

Häkkinen K (1994) Neuromuscular adaption during strength training, aging, detraining, and immobilization. Crit Rev Phys Rehabil Med 6:161–198

16.

Hayes A, Williams DA (1997) Contractile properties of clenbuterol-treated mdx muscle are enhanced by lowintensity swimming. J Appl Physiol 82:435–439PubMed

17.

Jacobs HM, Lutik A, Touw-Otten FWMM, de Melker RA (1990) [The sickness impact profile; results of an evaluation study of the Dutch version]. Ned Tijdschr Geneeskd 134:1950–1954PubMed

18.

Johnson EW, Braddom R (1971) Overwork weakness in facioscapulohumeral muscular dystrophy. Arch Phys Med Rehabil 52:333–336PubMed

19.

Kalkman JS, Schillings ML, van der Werf SP, et al. (2005) Experienced fatigue in facioscapulohumeral dystrophy, myotonic dystrophy and HMSN-I patients. J Neurol Neurosurg Psychiatry 76:1406–1409CrossRefPubMed

20.

Kissel JT, McDermott MP, Natarajan R, et al. (1998) Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology 50:1402–1406PubMed

21.

Kissel JT, McDermott MP, Mendell JR, et al. (2001) Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 57:1434–1440PubMed

22.

Koetsier CP (1997) [Pain related to FSH dystrophy. An underestimated problem? Results of an inquiry in the Netherlands]. Dutch Public Fund for Neuromuscular Disorders (VSN). Baarn

23.

Krupp LB (2003) Fatigue. Butterworth Heinemann, Philadelphia

24.

Lindeman E, Drukker J (1994) Speci- ficity of strength training in neuromuscular disorders. J Rehabil Sci 7:13–15

25.

McCartney N, Moroz D, Garner SH, McComas AJ (1988) The effects of strength training in patients with selected neuromuscular disorders. Med Sci Sports Exerc 20:362–368CrossRefPubMed

26.

McDonalds CM (2002) Physical activity, health impairments, and disability in neuromuscular disease. Am J Phys Med Rehabil 81:S108–S120CrossRef

27.

Melzack R (1975) The McGill Pain Questionnaire: major properties and scoring methods. Pain 1:277–299CrossRefPubMed

28.

Milner-Brown HS, Miller RG (1988) Muscle strengthening through highresistance weight training in patients with neuromuscular disorders. Arch Phys Med Rehabil 69:14–19PubMed

29.

Olsen DB, Orngreen MC, Vissing J (2005) Aerobic training improves exercise performance in facioscapulohumeral muscular dystrophy. Neurology 64:1064–1066PubMed

30.

Padberg GW (1982) Facioscapulohumeral disease [thesis]. Leiden University, Leiden

31.

Prins JB, Bleijenberg G, Bazelmans E, et al. (2001) Cognitive behaviour therapy for chronic fatigue syndrome: a multicentre randomised controlled trial. Lancet 357:841–847CrossRefPubMed

32.

Tawil R, McDermott MP, Pandya S, et al. (1997) A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group. Neurology 48:46–49PubMed

33.

Vanderiet K, Adriaensen H, Carton H, Vertommen H (1987) The McGill Pain Questionnaire constructed for the Dutch language (MPQ-DV). Preliminary data concerning reliability and validity. Pain 30:395–408CrossRefPubMed

34.

van der Kloot WA, Oostendorp RA, van der Meij J, van den Heuvel J (1995) [The Dutch version of the McGill pain questionnaire: a reliable pain questionnaire]. Ned Tijdschr Geneeskd 139:669–673PubMed

35.

van der Kooi EL, Vogels OJ, van Asseldonk RJ, et al. (2004) Strength training and albuterol in facioscapulohumeral muscular dystrophy. Neurology 63:702–708PubMed

36.

van Deutekom JC, Wijmenga C, van Tienhoven EA, et al. (1993) FSHD associated DNA rearrangements are due to deletions of integral copies of a 3.2 kb tandemly repeated unit. Hum Mol Genet 2:2037–2042CrossRefPubMed

37.

Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G (1994) Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 38:383–392CrossRefPubMed

38.

Vercoulen JH, Alberts M, Bleijenberg G (1999) [The Checklist Individual Strength (CIS)]. Gedragstherapie 32:131–136

39.

Vignos PJ Jr, Watkins MP (1966) The effect of exercise in muscular dystrophy. JAMA 197:843–848CrossRef

40.

Whooley MA, Simon GE (2000) Managing depression in medical outpatients. N Engl J Med 343:1942–1950CrossRefPubMed

41.

Wijmenga C, Hewitt JE, Sandkuijl LA, et al. (1992) Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy. Nat Genet 2:26–30CrossRefPubMed

42.

Wineski LE, von Deutsch DA, Abukhalaf IK, Pitts SA, Potter DE, Paulsen DF (2002) Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats. Cells Tissues Organs 171:188–198CrossRefPubMed

43.

Yang YT, McElligott MA (1989) Multiple actions of beta-adrenergic agonists on skeletal muscle and adipose tissue. Biochem J 261:1–10PubMed

Title: Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy
Authors: E. L. van der Kooi, MD
J. S. Kalkman, MSc
E. Lindeman, MD, PhD
J. C. M. Hendriks, PhD
B. G. M. van Engelen, MD, PhD
G. Bleijenberg, PhD
G. W. Padberg, MD, PhD
Publication date: 01-07-2007
Publisher: Steinkopff-Verlag
Published in: Journal of Neurology / Issue 7/2007
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-006-0432-4

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Effects of training and albuterol on pain and fatigue in facioscapulohumeral muscular dystrophy

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2007

Spread of primary dystonia in relation to initially affected region

Fatigue: an important feature of late-onset Pompe disease

Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis

A novel mutation in the SPG3A gene (atlastin) in hereditary spastic paraplegia

Post-deep brain stimulation — gradual non-stimulation dependent decrease in strength with attenuation of multiple sclerosis tremor

A novel mutation in the HSPD1 gene in a patient with hereditary spastic paraplegia